Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Par Pharmaceutical, Inc. ("Par") has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product. Par’s appeal of the District Court’s ruling on August 31, 2021, that Eagle’s vasopressin product does not infringe any of the patents asserted by Par against Eagle remains pending, and Eagle will continue to vigorously defend against such appeal.
"We look forward to advancing our launch plans for this important product, and we believe this withdrawal re-affirms our confidence in ultimate success," stated Scott Tarriff, President and Chief Executive Officer of Eagle.
https://finance.yahoo.com/news/eagle-pharmaceuticals-reports-par-unilaterally-163900086.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.